CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 44 enrolled
Drug / intervention
Oral Glucose Tolerance Testdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01409434
NCT01409434Phase 4Completed

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

University of Florida·interventional·Posted Aug 4, 2011·Updated Oct 16, 2014

In Brief

A Phase 4 clinical trial evaluating Oral Glucose Tolerance Test for Drug Induced Hyperglycemia and Secondary Hyperlipidemia. Completed, enrolled 44 participants across 1 site.

Detailed Summary

This is a research study of the long term effects on blood sugar and cholesterol of blood pressure lowering medications. People are invited to participate in this research study if they participated in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR 1, NCT00246519 or PEAR 2, NCT01203852) study and are still taking a thiazide diuretic. In PEAR, the effects on blood pressure, blood sugar, and cholesterol of the high blood pressure drugs hydrochlorothiazide and atenolol over an 18 week period were evaluated. This PEAR follow-up study will determine the effects of thiazide diuretics on blood sugar and cholesterol, but in the period since the PEAR trial. The study hypothesis is that long term exposure to thiazide diuretics results in larger increases in blood sugar and cholesterol levels than short term exposure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 4, 2011
Enrollment StartJun 1, 2010
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.9 years ago

Interventions

Oral Glucose Tolerance Testdrug

Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).